ProKidney Corp

NASDAQ:PROKUnited States

ProKidney Corp. is a clinical-stage biotechnology company. The Company is focused on cell therapy platforms capable of treating multiple chronic kidney diseases (CKD) using a patient’s own cells isolated from the patient intended for treatment. The Company’s lead product candidate, Renal Autologous Cell Therapy (REACT), is designed to preserve kidney function in a CKD patient’s diseased kidneys. REACT is a product that includes autologous Selected Renal Cells (SRCs) prepared from a patient’s own (autologous) kidney cells. The REACT injection is an investigational therapy that is a mixture of kidney cells prepared from the participant’s own kidney tissue. Its patented technology includes multiple breakthroughs in the manufacturing and medical delivery of cellular therapy products. It is conducting a global Phase 3 development program and multiple Phase 2 clinical trials for REACT in subjects with moderate to severe diabetic kidney disease (DKD).

Contact Information

Headquarters

2000 Frontis Plaza Blvd., Suite 250WINSTON-SALEM, NC, United States 27103

Phone

336-999-7028

Fax

---

Executives

Chairman of the Board

Pablo Legorreta

Chief Executive Officer, Director

Bruce Culleton

Chief Financial Officer

James Coulston

Executive Vice President - Technical Operations

Ulrich Ernst

Senior Vice President, Head of Global Clinical Development and Interventional Procedures

Joseph Stavas